Barclays analyst Etzer Darout raised the firm’s price target on AnaptysBio (ANAB) to $78 from $55 and keeps an Overweight rating on the shares. The firm cites increased conviction in ANB033 for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio assumed at Buy from Neutral at UBS
- These 3 Biotech Stocks Can Triple from Current Levels, Say Five-Star Analysts – 12/19/2025
- AnaptysBio price target raised to $140 from $100 at Guggenheim
- AnaptysBio price target lowered to $55 from $70 at Barclays
- AnaptysBio price target lowered to $56 from $80 at Stifel